Ernexa Therapeutics Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Ernexa Therapeutics Inc. (Nasdaq: ERNA), a preclinical-stage biotechnology company founded in 2018 and headquartered in Cambridge, Massachusetts, develops proprietary induced mesenchymal stem cell (iMSC) therapies derived from induced pluripotent stem cells (iPSCs) for oncology and autoimmune disease indications. The company's core platform engineers iPSCs into synthetic, allogeneic iMSCs that leverage the cells' natural tumor-homing or inflammation-targeting properties to deliver therapeutic cytokines directly to disease sites, enabling scalable off-the-shelf treatments without patient-specific harvesting; its lead product candidates include ERNA-101, an IL-7/IL-15 secreting iMSC designed to remodel the immunosuppressive tumor microenvironment, enhance immune cell activation, and treat platinum-resistant ovarian cancer alone or in combination with immunotherapies such as CAR-T, checkpoint inhibitors, or bispecific T-cell engagers; and ERNA-201 (also referenced as ERNA-102 in some disclosures), an IL-10 secreting iMSC to suppress chronic inflammation, reset immune overactivity, and address rheumatoid arthritis or other autoimmune conditions. Ernexa operates primarily in the United States with a focus on high-unmet-need patient populations in solid tumors and difficult-to-treat autoimmune disorders, maintaining a license agreement with Factor Bioscience Limited for supporting technologies. In recent developments, the company changed its name from Eterna Therapeutics Inc. to Ernexa Therapeutics in March 2025 to align with its refined clinical focus; announced a strategic manufacturing partnership with Cellipont Bioservices in October 2025 covering engineering, differentiation, and production activities to advance ERNA-101 toward first-in-human clinical trials; and reported improved year-over-year financial performance in its latest quarterly update while preparing presentations at key industry events including Oxford Global's Cell 2025 conference in November 2025.
Company News
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
Ernexa Therapeutics' ERNA-101 Selected for Flash Talk Presentation at Nature Conferences' Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center
Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy
Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D.
Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing
Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy
Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer
Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development
Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development